FDA approves Johnson & Johnson’s IMAAVY® as first-ever treatment for warm autoimmune hemolytic anemia, a landmark advancement
On Aug. 24, 2026, Johnson & Johnson announced the U.S. Food and Drug Administration (FDA) approval of IMAAVY®…
-
-
Biotechnology | FDA | Oncology | Therapeutics
The FDA approved Amgen’s Epogen/Procrit for the treatment of anemia
On Apr. 1, 1993, the U.S. Food and Drug Administration (FDA) approved Amgen’s Epogen/Procrit for the treatment of…
